In the first half (H1) of 2025, Abbott Laboratories performed well in the US medical device sector, with steady growth in its core product lines. According to leading data and analytics company GlobalData, some of Abbott’s high-volume product lines declined in average selling price (ASP) in the first six months of 2025, when compared to reporting from the same period last year. However, Abbott’s top revenue product lines maintained consistent ASPs across 2024 and 2025, which suggests that the company remains well-positioned and resistant to economic pressures, including those related to evolving tariff policies.
When analysing Abbott’s highest-volume products, some nuances emerge. Products that ranked highest by volume of sales in 2024 experienced modest increases in ASPs while those leading by volume in 2025 showed no change or a slight decline in ASPs. This pattern may reflect changing purchasing strategies among US healthcare facilities, potentially arising due to evolving priorities in public health and cost considerations.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
According to its recent financial report, Abbott delivered a strong first half in 2025, with its US medical device sales growing by 14.8% compared to H1 2024. GlobalData’s latest data indicates continued strong performance across several key product lines, including MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott holds approximately 18% market share, according to GlobalData.
Abbott’s US diagnostics saw a modest decline in year-over-year sales in the second quarter of 2025, specifically in point-of-care and rapid diagnostics. This appears to be linked to reduced demand for Covid-19 testing, which had previously seen high demand. This shift in demand could be responsible for the changes in some of Abbott’s high-volume sales.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
